Divi's Laboratories Limited (DIVISLAB) — Corporate Action | 17 May 2025

· NSE 🔴 High Importance ✨ Positive
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings

Divi's Laboratories reported FY2025 consolidated revenue of ₹9,712 crores, up 18.8% YoY, with PAT rising 37% to ₹2,191 crores. The board recommended a dividend of ₹30 per share (1500% payout), subject to AGM approval in August. New CFO Venkatesa Perumallu Pasumarthy assumes role August 1, 2025. Capex of ₹1,118 crores funded the Unit III greenfield project in Andhra Pradesh, now operational. Auditor issued an unmodified opinion with no material uncertainties.

📄 View Original Announcement (PDF)

About Divi's Laboratories Limited (DIVISLAB)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,79,470.03 Cr P/E: 72.4 ROE: 16.6% ROCE: 22.1%

View full DIVISLAB stock details →

📡 Get AI alerts when DIVISLAB files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track DIVISLAB — Free

📊 More DIVISLAB filings

See all DIVISLAB filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when DIVISLAB files new disclosures

Track DIVISLAB filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track DIVISLAB — Free

Free account · 2 AI queries/day